Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ISRCTN |
Last refreshed on:
|
13 January 2015 |
Main ID: |
ISRCTN57157825 |
Date of registration:
|
28/02/2001 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
International Collaborative Ovarian Neoplasm studies (3): a trial of paclitaxel with carboplatin in the first-line treatment of ovarian cancer
|
Scientific title:
|
|
Date of first enrolment:
|
27/03/1995 |
Target sample size:
|
2000 |
Recruitment status: |
Completed |
URL:
|
http://isrctn.com/ISRCTN57157825 |
Study type:
|
Interventional |
Study design:
|
Randomised controlled trial (Treatment)
|
Phase:
|
|
|
Countries of recruitment
|
United Kingdom
| | | | | | | |
Contacts
|
Name:
|
Claire
Amos |
Address:
|
MRC Clinical Trials Unit
222 Euston Road
NW1 2DA
London
United Kingdom |
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. Chemotherapy indicated 2. No previous chemotherapy or radiotherapy 3. No contraindication to chemotherapy
Exclusion criteria: Does not meet inclusion criteria
Age minimum:
Age maximum:
Gender:
Female
|
Health Condition(s) or Problem(s) studied
|
Cancer Cancer Ovarian cancer
|
Intervention(s)
|
1. One group receives paclitaxel in combination with carboplatin 2. The other group receives a control treatment of either single-agent carboplatin or CAP (cyclophosphamide, doxorubicin and cisplatin)
|
Primary Outcome(s)
|
Survival time - time to progression, quality of life, health economics
|
Secondary Outcome(s)
|
Not provided at time of registration
|
Source(s) of Monetary Support
|
Medical Research Council (MRC) (UK)
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|